US 8,883,980 B2 · Antigen binding molecules with increased Fc receptor binding affinity and effector function

Abstract

The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.

Claims16

Dependent claims

An antibody that binds to human CD20 comprising:

(a) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:40;
and
(b) a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:76.

Dependencies are inferred from the claim text.

Facts

Application

11/889,975Filed 17 Aug 2007 · division

Priority

5 Nov 2003

Published

US 2009/0010921 A18 Jan 2009

Granted

11 Nov 2014

Term ends

Not estimatedThe source records don’t support an estimate.

Classification63 codes

C07K 16/2887
Against receptors, cell surface antigens or cell surface determinants: against CD20
A61P 1/04
Drugs for disorders of the alimentary tract or the digestive system: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of…
A61P 1/16
Drugs for disorders of the alimentary tract or the digestive system: for liver or gallbladder disorders, e.g. hepatoprotective agents,…
A61P 3/10
For glucose homeostasis: for hyperglycaemia, e.g. antidiabetics

Family

Application60/517,096Us provisional application · filed 5 Nov 2003

Application10/981,738Parent of this division · filed 5 Nov 2004

US 2009/0010921 A1Pre-grant publication · published 8 Jan 2009

US 2005/0123546 A1Published application

US 9,296,820 B2Related patent

US 8,883,980 B2This patent

From the US filing history. Foreign family members aren’t listed.

Antigen binding molecules with increased Fc receptor binding affinity and effector function

Life of this patent

Antigen binding molecules with increased Fc receptor binding affinity and effector function

Life of this patent

Abstract

Claims16